Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Proc Natl Acad Sci U S A ; 108(46): 18843-8, 2011 Nov 15.
Article in English | MEDLINE | ID: mdl-21976485

ABSTRACT

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene that impair the function of CFTR, an epithelial chloride channel required for proper function of the lung, pancreas, and other organs. Most patients with CF carry the F508del CFTR mutation, which causes defective CFTR protein folding and processing in the endoplasmic reticulum, resulting in minimal amounts of CFTR at the cell surface. One strategy to treat these patients is to correct the processing of F508del-CFTR with small molecules. Here we describe the in vitro pharmacology of VX-809, a CFTR corrector that was advanced into clinical development for the treatment of CF. In cultured human bronchial epithelial cells isolated from patients with CF homozygous for F508del, VX-809 improved F508del-CFTR processing in the endoplasmic reticulum and enhanced chloride secretion to approximately 14% of non-CF human bronchial epithelial cells (EC(50), 81 ± 19 nM), a level associated with mild CF in patients with less disruptive CFTR mutations. F508del-CFTR corrected by VX-809 exhibited biochemical and functional characteristics similar to normal CFTR, including biochemical susceptibility to proteolysis, residence time in the plasma membrane, and single-channel open probability. VX-809 was more efficacious and selective for CFTR than previously reported CFTR correctors. VX-809 represents a class of CFTR corrector that specifically addresses the underlying processing defect in F508del-CFTR.


Subject(s)
Aminopyridines/therapeutic use , Benzodioxoles/therapeutic use , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis/drug therapy , Mutation , Bronchi/cytology , Cell Line , Cells, Cultured , Chemistry, Pharmaceutical/methods , Chlorides/chemistry , Cystic Fibrosis/genetics , Drug Design , Drug Evaluation, Preclinical , Epithelial Cells/cytology , Homozygote , Humans , In Vitro Techniques , Lung/pathology , Models, Genetic
2.
J Oral Implantol ; 35(6): 270-6, 2009.
Article in English | MEDLINE | ID: mdl-20017642

ABSTRACT

Dental implants have enabled a dramatic increase in the quality of life for many partially edentulous and edentulous patents. Immediate loading of newly placed dental implants is a recent advancement that attempts to meet patient demand. However, immediate loading of a just placed implant may induce implant failure to osseointegrate. Some patients can generate a biting force that can reach approximately 1300 Newtons (N) in the posterior jaws. The magnitude of bite force that would cause failure of osseointegration of newly placed implants is currently unknown. It has been proposed that osseointegration would fail if an implant is luxated in bone more than 50 to 150 microns. Fibrous tissue, not bone, would form. This study investigated the quantity of various off-axial forces required to move a nonosseointegrated 4.3 x 13 mm implant 50 microns. The previously published pilot study for this study found that the amount of horizontal force required to displace an implant 50 microns was approximately 150 N. This study found that the force needed to move the implants 100 microns at a horizontal approach, 0 degrees, averaged 50 N, with a range of 23-79 N; at 22 degrees, averaged 52 N, with a range of 27-70 N; and at 60 degrees averaged 87 N, with a range of 33-105 N.


Subject(s)
Dental Implants , Mandible/pathology , Animals , Biomechanical Phenomena , Bite Force , Cattle , Imaging, Three-Dimensional , Materials Testing/instrumentation , Materials Testing/methods , Mechanical Phenomena , Movement , Osseointegration , Signal Processing, Computer-Assisted , Stress, Mechanical , Transducers
3.
Anal Biochem ; 355(2): 267-77, 2006 Aug 15.
Article in English | MEDLINE | ID: mdl-16797469

ABSTRACT

This report describes the development, optimization, and implementation of a miniaturized cell-based assay for the identification of small-molecule insulin mimetics and potentiators. Cell-based assays are attractive formats for compound screening because they present the molecular targets in their cellular environment. A fluorescence resonance energy transfer (FRET) cell-based assay that measures the insulin-dependent colocalization of Akt2 fused with either cyan fluorescent protein or yellow fluorescent protein to the cellular membrane was developed. This ratiometric FRET assay was miniaturized into a robust, yet sensitive 3456-well nanoplate assay with Z' factors of approximately 0.6 despite a very small assay window (less than twofold full activation with insulin). The FRET assay was used for primary screening of a large compound collection for insulin-receptor agonists and potentiators. To prioritize compounds for further development, primary hits were tested in two additional assays, a biochemical time-resolved fluorescence resonance energy transfer assay to measure insulin-receptor phosphorylation and a translocation-based imaging assay. Results from the three assays were combined to yield 11 compounds as potential leads for the development of insulin mimetics or potentiators.


Subject(s)
Biological Assay/methods , Cell Membrane/metabolism , Fluorescence Resonance Energy Transfer/methods , Insulin/metabolism , Receptor, Insulin/metabolism , Active Transport, Cell Nucleus/physiology , Animals , Bacterial Proteins/chemistry , Bacterial Proteins/metabolism , CHO Cells , Cricetinae , Green Fluorescent Proteins/chemistry , Green Fluorescent Proteins/metabolism , Luminescent Proteins/chemistry , Luminescent Proteins/metabolism , Nanotechnology , Phosphorylation , Proto-Oncogene Proteins c-akt/chemistry , Proto-Oncogene Proteins c-akt/metabolism , Receptor, Insulin/analysis , Time Factors
4.
Am J Physiol Lung Cell Mol Physiol ; 290(6): L1117-30, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16443646

ABSTRACT

Cystic fibrosis (CF) is a fatal genetic disease caused by mutations in cftr, a gene encoding a PKA-regulated Cl(-) channel. The most common mutation results in a deletion of phenylalanine at position 508 (DeltaF508-CFTR) that impairs protein folding, trafficking, and channel gating in epithelial cells. In the airway, these defects alter salt and fluid transport, leading to chronic infection, inflammation, and loss of lung function. There are no drugs that specifically target mutant CFTR, and optimal treatment of CF may require repair of both the folding and gating defects. Here, we describe two classes of novel, potent small molecules identified from screening compound libraries that restore the function of DeltaF508-CFTR in both recombinant cells and cultures of human bronchial epithelia isolated from CF patients. The first class partially corrects the trafficking defect by facilitating exit from the endoplasmic reticulum and restores DeltaF508-CFTR-mediated Cl(-) transport to more than 10% of that observed in non-CF human bronchial epithelial cultures, a level expected to result in a clinical benefit in CF patients. The second class of compounds potentiates cAMP-mediated gating of DeltaF508-CFTR and achieves single-channel activity similar to wild-type CFTR. The CFTR-activating effects of the two mechanisms are additive and support the rationale of a drug discovery strategy based on rescue of the basic genetic defect responsible for CF.


Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis/physiopathology , 3T3 Cells , Animals , Biotinylation , Cell Line , Cells, Cultured , Chlorides/metabolism , Cresols/metabolism , Cystic Fibrosis/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/physiology , Humans , Ion Channel Gating , Mice , Pyrazoles/metabolism , Rats , Recombinant Proteins/metabolism , Sequence Deletion , Thyroid Gland/physiology
5.
J Immunol ; 175(4): 2630-4, 2005 Aug 15.
Article in English | MEDLINE | ID: mdl-16081838

ABSTRACT

Familial cold autoinflammatory syndrome (FCAS) and the related autoinflammatory disorders, Muckle-Wells syndrome and neonatal onset multisystem inflammatory disease, are characterized by mutations in the CIAS1 gene that encodes cryopyrin, an adaptor protein involved in activation of IL-converting enzyme/caspase-1. Mutations in cryopyrin are hypothesized to result in abnormal secretion of caspase-1-dependent proinflammatory cytokines, IL-1beta and IL-18. In this study, we examined cytokine secretion in PBMCs from FCAS patients and found a marked hyperresponsiveness of both IL-1beta and IL-18 secretion to LPS stimulation, but no evidence of increased basal secretion of these cytokines, or alterations in basal or stimulated pro-IL-1beta levels. VX-765, an orally active IL-converting enzyme/caspase-1 inhibitor, blocked IL-1beta secretion with equal potency in LPS-stimulated cells from FCAS and control subjects. These results further link mutations in cryopyrin with abnormal caspase-1 activation, and support the clinical testing of caspase-1 inhibitors such as VX-765 in autoinflammatory disorders.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Autoimmune Diseases/immunology , Caspase Inhibitors , Cold Temperature/adverse effects , Cysteine Proteinase Inhibitors/pharmacology , Hypersensitivity/prevention & control , Monocytes/pathology , Adult , Aged , Aged, 80 and over , Autoimmune Diseases/enzymology , Autoimmune Diseases/genetics , Carrier Proteins/genetics , Carrier Proteins/physiology , Caspase 1/biosynthesis , Caspase 1/physiology , Cytokines/metabolism , Drug Evaluation, Preclinical , Female , Humans , Hypersensitivity/enzymology , Hypersensitivity/genetics , Hypersensitivity/immunology , Inflammation/enzymology , Inflammation/genetics , Inflammation/prevention & control , Interleukin-1/antagonists & inhibitors , Interleukin-1/biosynthesis , Interleukin-1/metabolism , Lipopolysaccharides/pharmacology , Male , Middle Aged , Monocytes/enzymology , Monocytes/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein , Prodrugs/pharmacology , Protein Precursors/biosynthesis , Syndrome
6.
Hum Mol Genet ; 14(14): 2003-18, 2005 Jul 15.
Article in English | MEDLINE | ID: mdl-15944201

ABSTRACT

We have exploited the existence of a second copy of the human SMN gene (SMN2) to develop a high-throughput screening strategy to identify potential small molecule therapeutics for the genetic disease spinal muscular atrophy (SMA), which is caused by the loss of the SMN1 gene. Our screening process was designed to identify synthetic compounds that increase the total amount of full-length SMN messenger RNA and protein arising from the SMN2 gene, thereby suppressing the deleterious effects of losing SMN1. A cell-based bioassay was generated that detects SMN2 promoter activity, on which greater than 550,000 compounds was tested. This resulted in the identification of 17 distinct compounds with confirmed biological activity on the cellular primary assay, belonging to nine different structural families. Six of the nine scaffolds were chosen on the basis of their drug-like features to be tested for their ability to modulate SMN gene expression in SMA patient-derived fibroblasts. Five of the six compound classes altered SMN mRNA levels or mRNA splicing patterns in SMA patient-derived fibroblasts. Two of the compound classes, a quinazoline compound series and an indole compound, also increased SMN protein levels and nuclear gem/Cajal body numbers in patient-derived cells. In addition, these two distinct scaffolds showed additive effects when used in combination, suggesting that they may act on different molecular targets. The work described here has provided the foundation for a successful medicinal chemistry effort to further advance these compounds as potential small molecule therapeutics for SMA.


Subject(s)
Cyclic AMP Response Element-Binding Protein/genetics , Muscular Atrophy, Spinal/genetics , Nerve Tissue Proteins/genetics , RNA-Binding Proteins/genetics , Base Sequence , Blotting, Western , Cells, Cultured , Coiled Bodies/metabolism , DNA Primers , Dose-Response Relationship, Drug , Humans , Immunohistochemistry , Muscular Atrophy, Spinal/drug therapy , Promoter Regions, Genetic , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction , SMN Complex Proteins , Survival of Motor Neuron 1 Protein , Survival of Motor Neuron 2 Protein
7.
Iowa Orthop J ; 24: 36-42, 2004.
Article in English | MEDLINE | ID: mdl-15296204

ABSTRACT

Segmental bone defects are challenging clinical problems, and current surgical solutions are associated with high complication rates. In oncologic reconstructive surgery, bone healing will occur coincidently with the administration of chemotherapy to treat the underlying disease. Effective methods of graft modification or bone graft alternatives can be of great help clinically. A series of osteoinductive proteins (bone morphogenetic proteins or BMPs) has been described and shown to enhance bone formation in animal models. This study was designed to evaluate the effect of chemotherapy on bone healing enhanced by rhBMP-2. We used a critical-sized bone-defect rabbit model. Histological and radiological analysis showed that chemotherapy affects both the quantity and the quality of the bone enhanced by the addition of rhBMP-2. These results suggest that the effect of chemotherapy on bone formation could be related to inhibition in a specific pathway stimulated by the rhBMP-2.


Subject(s)
Antibiotics, Antineoplastic/pharmacology , Antineoplastic Agents/pharmacology , Bone Morphogenetic Proteins/physiology , Bone Neoplasms/drug therapy , Bone and Bones/drug effects , Cisplatin/pharmacology , Doxorubicin/pharmacology , Transforming Growth Factor beta , Animals , Antibiotics, Antineoplastic/therapeutic use , Antineoplastic Agents/therapeutic use , Bone Morphogenetic Protein 2 , Bone Morphogenetic Proteins/administration & dosage , Bone and Bones/pathology , Rabbits
8.
J Biomol Screen ; 7(2): 149-54, 2002 Apr.
Article in English | MEDLINE | ID: mdl-12026885

ABSTRACT

This report describes the development of a cell-based assay for high-throughput screening and detection of small-molecule inhibitors for hepatitis C virus (HCV) NS2/3 protease. The HCV NS2/3 protease is essential for the normal infectious cycle of HCV. Generation of a cell-based assay for this cis-acting viral protease involved reporter constructs in which the NS2/3 protease sequence was inserted between the ,B-lactamase (BLA) reporter and a ubiquitin-based destabilization domain. In stable cell lines, NS2/3 cis cleavage of the NS2/3-BLA fusion protein resulted in differential stability of the cleaved versus uncleaved BLA reporter, providing a robust readout for protease activity. BLA reporter activity was shown to be a function of NS2/3-specific protease activity, by using genetic mutants of the NS2/3 sequence. In addition, the cell-based assay was validated and screened in a 384-well format on a fully automated robotic platform where small-molecule inhibitors of NS2/3 protease activity were identified.


Subject(s)
Cysteine Endopeptidases/metabolism , Drug Evaluation, Preclinical/methods , Hepacivirus/metabolism , Protease Inhibitors/pharmacology , Automation , Cycloheximide/pharmacology , Dose-Response Relationship, Drug , Genes, Reporter , Humans , Jurkat Cells , Models, Genetic , Mutation , Plasmids/metabolism , Protein Structure, Tertiary , Protein Synthesis Inhibitors/pharmacology , Recombinant Fusion Proteins/metabolism
9.
Assay Drug Dev Technol ; 1(1 Pt 1): 9-19, 2002 Nov.
Article in English | MEDLINE | ID: mdl-15090152

ABSTRACT

Protein phosphorylation is one of the major regulatory mechanisms involved in signal-induced cellular events, including cell proliferation, apoptosis, and metabolism. Because many facets of biology are regulated by protein phosphorylation, aberrant kinase and/or phosphatase activity forms the basis for many different types of pathology. The disease relevance of protein kinases and phosphatases has led many pharmaceutical and biotechnology companies to expend significant resources in lead discovery programs for these two target classes. The existence of >500 kinases and phosphatases encoded by the human genome necessitates development of methodologies for the rapid screening for novel and specific compound inhibitors. We describe here a fluorescence-based, molecular assay platform that is compatible with robotic, ultra-high throughput screening systems and can be applied to virtually all tyrosine and serine/threonine protein kinases and phosphatases. The assay has a coupled-enzyme format, utilizing the differential protease sensitivity of phosphorylated versus nonphosphorylated peptide substrates. In addition to screening individual kinases, the assay can be formatted such that kinase pathways are re-created in vitro to identify compounds that specifically interact with inactive kinases. Miniaturization of this assay format to the 1-microl scale allows for the rapid and accurate compound screening of a host of kinase and phosphatase targets, thereby facilitating the hunt for new leads for these target classes.


Subject(s)
Biological Assay/instrumentation , Drug Evaluation, Preclinical/instrumentation , Peptide Library , Phosphoprotein Phosphatases/chemistry , Protein Kinases/chemistry , Sulfonamides , Adenosine Triphosphate/physiology , Animals , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Fluorescence , Humans , Isoquinolines/pharmacology , Marine Toxins , Microcystins , Peptides, Cyclic/pharmacology , Phosphoprotein Phosphatases/antagonists & inhibitors , Protein Kinase Inhibitors , Protein Kinases/physiology , Signal Transduction/physiology , Staurosporine/pharmacology , Vanadates/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...